

Milvia Casato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8062943/publications.pdf>

Version: 2024-02-01

54
papers

1,763
citations

393982

19
h-index

276539

41
g-index

54
all docs

54
docs citations

54
times ranked

1731
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	3.6	167
2	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	0.6	149
3	Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. <i>American Journal of Medicine</i> , 1987, 83, 726-730.	0.6	145
4	Predictors of Long-Term Response to High-Dose Interferon Therapy in Type II Cryoglobulinemia Associated With Hepatitis C Virus Infection. <i>Blood</i> , 1997, 90, 3865-3873.	0.6	129
5	Hepatitis C Virus Drives the Unconstrained Monoclonal Expansion of VH1-69-Expressing Memory B Cells in Type II Cryoglobulinemia: A Model of Infection-Driven Lymphomagenesis. <i>Journal of Immunology</i> , 2005, 174, 6532-6539.	0.4	97
6	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	2.5	87
7	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	2.5	87
8	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	3.0	83
9	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	1.8	73
10	Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. <i>Blood</i> , 2002, 99, 2259-2261.	0.6	68
11	Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. <i>Journal of Rheumatology</i> , 2005, 32, 484-8.	1.0	68
12	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011, 10, 714-719.	2.5	64
13	Efficacy of low-dose rituximab for mixed cryoglobulinemia. <i>Clinical Immunology</i> , 2007, 125, 30-33.	1.4	55
14	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	2.5	53
15	Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21 ^{low} cells overexpressing Stra13. <i>European Journal of Immunology</i> , 2012, 42, 1468-1476.	1.6	40
16	Mixed cryoglobulinemia secondary to visceral Leishmaniasis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2007-2011.	6.7	33
17	Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. <i>Liver International</i> , 2019, 39, 628-632.	1.9	31
18	Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 430-435.	2.5	30

#	ARTICLE	IF	CITATIONS
19	Reversion of anergy signatures in clonal CD21 ^{low} B cells of mixed cryoglobulinemia after clearance of HCV viremia. <i>Blood</i> , 2017, 130, 35-38.	0.6	26
20	Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer. <i>Rheumatology</i> , 2018, 57, 1870-1871.	0.9	19
21	Interferon for Hepatitis C Virus–Negative Type II Mixed Cryoglobulinemia. <i>New England Journal of Medicine</i> , 1998, 338, 1386-1387.	13.9	17
22	Persistence of a Large Population of Exhausted Monoclonal B cells in Mixed Cryoglobuliemia After the Eradication of Hepatitis C Virus Infection. <i>Journal of Clinical Immunology</i> , 2012, 32, 729-735.	2.0	17
23	Analysis of Hepatitis C Virus Hypervariable Region 1 Sequence from Cryoglobulinemic Patients and Associated Controls. <i>Journal of Virology</i> , 2007, 81, 4564-4571.	1.5	16
24	The VH1-69–expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21 ^{low} phenotype. <i>Blood</i> , 2011, 118, 3440-3441.	0.6	14
25	Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. <i>Clinical Rheumatology</i> , 2017, 36, 617-623.	1.0	13
26	Influence of age and autoimmunity on liver disease in HCV-associated type II mixed cryoglobulinemia. <i>Human Immunology</i> , 2002, 63, 751-757.	1.2	12
27	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 441-443.	0.5	12
28	Analysis of the Dynamics of Cryoaggregation by Light-Scattering Spectrometry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 152-8.	1.4	11
29	DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells. <i>Immunology Letters</i> , 2018, 198, 7-11.	1.1	11
30	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , 2020, 21, 131-135.	2.2	11
31	Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S28-32.	0.4	11
32	Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 614-20.	1.4	10
33	Reply. <i>Hepatology</i> , 2017, 65, 1771-1772.	3.6	10
34	CD21 ^{low} B cells are predictive markers of new digital ulcers in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 205, 128-134.	1.1	10
35	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2022, 117, 627-636.	0.2	9
36	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab BiosimiLar). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Clinico-immunological outcomes of HCV-cured cryoglobulinemia: Lower relapse rate with interferon-based than interferon-free therapy. <i>Liver International</i> , 2021, 41, 70-75.	1.9	8
38	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.	2.5	8
39	Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia. <i>Vaccine Journal</i> , 2003, 10, 70-77.	3.2	7
40	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2021, 96, E210-E214.	2.0	7
41	Clinical effects of interferon in patients with idiopathic mixed cryoglobulinemia. <i>European Journal of Haematology</i> , 1990, 45, 7-8.	1.1	5
42	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , 2015, 126, 3938-3938.	0.6	5
43	Cryoglobulins: putative effectors of adaptive immune response. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 171-179.	0.4	5
44	From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?. <i>Expert Review of Hematology</i> , 2017, 10, 719-727.	1.0	4
45	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	0.9	4
46	HCV infection in a patient with hyper-IgM syndrome. <i>Journal of Clinical Immunology</i> , 1996, 16, 321-325.	2.0	3
47	The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy. <i>Hepatology</i> , 2015, 62, 975-975.	3.6	3
48	HBV messing with the B-cell genome leads to DLBCL. <i>Blood</i> , 2018, 131, 2602-2603.	0.6	3
49	Persistence of Pathogenic B-Cell Clones and Relapse of Cryoglobulinemic Vasculitis in HCV-Cured Patients. <i>Gastroenterology</i> , 2019, 156, 291.	0.6	2
50	Rheumatoid factor-producing CD21 ^{low} anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and non-infectious cryoglobulinaemias. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 139-147.	0.4	1
51	Cryoglobulins: putative effectors of adaptive immune response. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 171-179.	0.4	1
52	Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 149-154.	0.4	1
53	CRYOGLOBULINAEMIA AND ALPHA-INTERFERON. <i>Lancet, The</i> , 1988, 332, 274-275.	6.3	0
54	Letters to the Editor. <i>Journal of Hepatology</i> , 2000, 33, 1027-1028.	1.8	0